WO2005035525B1 - 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease - Google Patents

2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Info

Publication number
WO2005035525B1
WO2005035525B1 PCT/US2004/029093 US2004029093W WO2005035525B1 WO 2005035525 B1 WO2005035525 B1 WO 2005035525B1 US 2004029093 W US2004029093 W US 2004029093W WO 2005035525 B1 WO2005035525 B1 WO 2005035525B1
Authority
WO
WIPO (PCT)
Prior art keywords
aliphatic
independently
compound according
aryl
heteroaryl
Prior art date
Application number
PCT/US2004/029093
Other languages
French (fr)
Other versions
WO2005035525A3 (en
WO2005035525A2 (en
Filing date
Publication date
Priority to NZ545158A priority Critical patent/NZ545158A/en
Priority to BRPI0414176-8A priority patent/BRPI0414176A/en
Priority to EP04809688A priority patent/EP1667998A2/en
Priority to JP2006525519A priority patent/JP4767852B2/en
Priority to CA2536436A priority patent/CA2536436C/en
Priority to MXPA06002476A priority patent/MXPA06002476A/en
Priority to AU2004279800A priority patent/AU2004279800B9/en
Priority to CN2004800254182A priority patent/CN1845920B/en
Application filed filed Critical
Publication of WO2005035525A2 publication Critical patent/WO2005035525A2/en
Publication of WO2005035525A3 publication Critical patent/WO2005035525A3/en
Priority to IL173627A priority patent/IL173627A0/en
Priority to NO20061426A priority patent/NO20061426L/en
Publication of WO2005035525B1 publication Critical patent/WO2005035525B1/en
Priority to HK07102734.0A priority patent/HK1095594A1/en

Links

Abstract

The present invention relates to compounds of formula I-A and I-B that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

Claims

AMENDED CLAIMS[received by the International Bureau on 26 October 2005 (26.10.2005); original claims 1-40 replaced by amended claims 1-40 (46 pages)]We claim :
1 . A compound of formula I :
Figure imgf000002_0001
wherein:
Ar is a 5- to 10-membered aromatic ring having up to 4 heteroatoms selected from O, S, N(H), SO, and SO2, wherein 1 to 3 ring atoms are optionally and independently substituted with J; R1 and R2 are independently: (C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-C10) -cycloalkyl- or -cycloalkenyl] - (C1-C12) - aliphatic-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C6-C10) -heteroaryl- (C1-C12)aliphatic-, wherein up to 3 aliphatic carbon atoms in R1 and R2 may be replaced by a heteroatom selected from 0, N, S, SO, or SO2 in a chemically stable arrangement; wherein each of R1 and R2 is independently and optionally substituted with up to 3 substituents independently selected from J;
R3 and R3' are independently hydrogen or (C1-C12) - aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R3 is optionally substituted with sulfhydryl or hydroxy; or R3 is phenyl or -CH2phenyl, wherein said phenyl group 151 is optionally substituted with up to 3 substituents independently selected from J; or
R3 and R3' together with the atom to which they are bound is a 3- to β-membered ring having up to 2 heteroatoms selected from N, NH, 0, SO, and SO2; wherein the ring has up to 2 substituents selected independently from J;
R4 and R4' are independently: hydrogen-, (C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl- or -cycloalkenyl- , (C3-C10) -cycloalkyl- (C1-C12) -aliphatic-, (C6-C10) -aryl-, (C3-C10) -heterocyclyl-; or (C5-C10) -heteroaryl-; wherein up to two aliphatic carbon atoms in R4 and R4' may be replaced by a heteroatom selected from 0, N, S, SO, and SO2; wherein each of R4 and R4' is independently and optionally substituted with up to 3 substituents independently selected from J;
Figure imgf000003_0001
wherein each R6 is independently : hydrogen- , 152
(C1-C12) -aliphatic-,
(C6-C10) -aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic- ,
(C3-C10) -cycloalkyl- or cycloalkenyl-,
[ (C3-C10) -cycloalkyl- or cycloalkenyl] - (C1-C12) - aliphatic-,
(C3-C10) -heterocyclyl-,
(C3-C10) -heterocyclyl- (C1-C12) -aliphatic-,
(C5-C10) heteroaryl-, or
(C5-C10)heteroaryl- (C1-C12) -aliphatic-, or two R6 groups, which are bound to the same nitrogen atom, form together with that nitrogen atom, a (C3-C10) -heterocyclic ring; wherein R6 is optionally substituted with up to 3 J substituents; wherein each R8 is independently -OR' ; or the R8 groups together with the boron atom, is a (C3-C10) - membered heterocyclic ring having in addition to the boron up to 3 additional heteroatoms selected from N, NH, 0, SO, and SO2;
T is:
(C1-C12) -aliphatic-;
(C6-C10) -aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-,
(C5-C10)heteroaryl-, or
(C5-ClO) heteroaryl- (C1-C12) -aliphatic-; wherein each T is optionally substituted with up to 3 J substituents;
J is halogen, -OR1, -NO2, -CN, -CF3, -OCF3, -R1, oxo, thioxo, 1, 2-methylenedioxy, 1 , 2-ethylenedioxy, =N(R') , =N(0R') , -N(R')2, -SR1 , -SOR' , -SO2R' , -SO2N(R1J2, -SO3R- , -C(O)R' , -C(O)C(O)R' , -C(O)CH2C(O)R' , -C(S)R' , 153
-C(S)OR', -C(O)OR1, -C(O)C(O)OR1, -C (0) C (0) N (R • ) 2,
-OC(O)R1, -C(O)N(RM2, -0C(0)N(R1)2, -C(S)N(R1J2,
- (CH2) 0-2NHC(O) R1 , -N(R' ) N (R1) COR' , -N (R ' ) N (R ' ) C (0) OR' ,
-N(R1 ) N(R1 JCON(R1 ) 2, -N (R1) SO2R1, -N (R ' ) SO2N (R ' ) 2 ,
-N(R1JC(O)OR1, -N(R1 )C(O)R' , -N(R1JC(S)R1,
-N(R1 )C(O)N(R' )2, -N(R1JC(S)N(RM2, -N(CORMCOR1,
-N(OR')R', -C(=NH)N(R' )2, -C(O)N(ORMR1, -C(=NOR')R',
-OP(O) (ORM2, -P(O) (RM2, -P(O) (ORM2, Or -P(O) (H) (OR') ;
R1 is: hydrogen- ,
(C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl- or -cycloalkenyl- ,
[ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12) - aliphatic-,
(C6-C10) -aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic- ,
(C3-C10) -heterocyclyl-,
(C6-C10) -heterocyclyl- (C1-C12) aliphatic-,
(C5-C10) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic- ; wherein R1 is optionally substituted with up to 3 J groups; wherein two R1 groups bound to the same atom form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, 0, S, SO, or SO2, wherein said ring is optionally fused to a (C6-C10) aryl, (C5- ClOJheteroaryl, (C3-C10) cycloalkyl, or a (C3- ClO)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J.
2. A compound of formula I :
Figure imgf000006_0001
wherein: n is 0 or 1;
Ar is a 5- to 10-membered aromatic ring having up to 4 heteroatoms selected from 0, S, N(H) , SO, and SO2, wherein 1 to 3 ring atoms are optionally and independently substituted with J; R1, R2, R12, and R13 are independently: (C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl- or -cycloalkenyl-, [ (C3-C10) -cycloalkyl- or -cycloalkenyl] - (C1-C12) - aliphatic-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C6-C10) -heteroaryl- (C1-C12) aliphatic-, wherein up to 3 aliphatic carbon atoms in R1 and R2 may be replaced by a heteroatom selected from 0, N, NH, S, SO, or SO2 in a chemically stable arrangement; wherein each of R1 and R2 is independently and optionally substituted at each substitutable position with up to 3 substituents independently selected from
J;
R3 and R3' are independently hydrogen or (C1-C12) - aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R3 is optionally substituted with sulfhydryl or hydroxy; or R3 is phenyl or -CH2phenyl, wherein said phenyl group is optionally substituted with up to 3 substituents independently selected from J; or
R3 and R3' together with the atom to which they are bound is a 3- to 6-membered ring having up to 2 heteroatoms 155 selected from N, NH, 0, SO, and SO2; wherein the ring has up to 2 substituents selected independently from J;
R4 and R4' are independently: rrydrogen- , (C1-C12) -aliphatic-,
(C3-C10) -cycloalkyl- or -cycloalkenyl- , (C3-C10) -cycloalkyl- (C1-C12) -aliphatic-, (C6-C10) -aryl-, (C3-C10) -heterocyclyl-; or (C5-C10) -heteroaryl-; wherein up to two aliphatic carbon atoms in R4 and R4' may be replaced by a heteroatom selected from 0, N, S, SO, and SO2; wherein each of R4 and R4' is independently and optionally substituted with up to 3 substituents independently selected from J;
Figure imgf000007_0001
wherein
Y is -CO2H, a derivative of -CO2H, or a bioisostere of -CO2H; each R6 is independently : hydrogen- , 156
(C1-C12) -aliphatic-, (C6-C1O) -aryl-,
(Cβ-CIO) -aryl- (C1-C12) aliphatic- , (C3-C1O) -cycloalkyl- or cycloalkenyl-, [ (03-C-LO) -cycloalkyl- or cycloalkenyl] - (C1-C12) - aliphatic- ,
(C3-C1O) -heterocyclyl-,
(C3-C1O) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10)heteroaryl-, or
(C5-C10)heteroaryl- (C1-C12) -aliphatic-, or two R6 groups, which are bound to the same nitrogen atom, form together with that nitrogen atom, a (C3-ClO) -heterocyclic ring; wherein R6 is optionally substituted with up to 3 J substituents; wherein each R8 is independently -OR1; or the R8 groups together with the boron atom, is a (C3-C10)- membered heterocyclic ring having in addition to the boron up to 3 additional heteroatoms selected from N, NH, 0, SO, and SO2;
T is:
(C1-C12) -aliphatic-;
(C6-C10) -ar-yl-,
(C6-C10) -ar-yl- (C1-C12) aliphatic-,
(C5-C10)heteroaryl-, or
(C5-C10)heteroaryl- (C1-C12) -aliphatic-; wherein each T is optionally substituted with up to 3 J substituents; and wherein up to 3 aliphatic carbon atoms in T may be replaced by a heteroatom selected from 0, N, NH, S, SO, or SO2 in a chemically stable arrangement; provided that if T is pyrrole, the pyrrole is not substituted at the 3-position with J, with J being 157
-C(O)R' , -C(O)C(O)R' , -C(O)CH2C(O)R' , -C(S)R1 , -C(S)OR' , -C(O)OR' , -C(O)C(O)OR', -C(O)C(O)N(R' J2, -C(O)N(R1J2, -C(S)N(R')2, -C(=NH)N(R') 2, -C (0) N (OR ' ) R ' , -C (=NOR ' ) R ' ;
J is halogen, -OR' , -NO2, -CN, -CF3, -OCF3, -R1 , oxo, thioxo, 1, 2-methylened±oxy, 1 , 2-ethylenedioxy, =N(R') , =N(0R') , -N(R')2, -SR' , -SOR' , -SO2R' , -SO2N(R')2, -SO3R' , -C(O)R' , -C(O)C(O)R' , -C(O)CH2C(O)R' , -C(S)R' , -C(S)OR1 , -C(O)OR' , -C (O)C(O)OR1 , -C (0) C (0) N (R ■ ) 2, -OC(O)R' , -C(O)N(R1J2, -OC(O)N(R1J2, -C(S)N(R')2, - (CH2) 0-2NHC (O)R' , -N(R1 )N(R')C0R' , -N (R ' ) N (R' ) C (0) OR ' , -N(R' ) N(R' ) CON(R' ) 2, -IST (R ' ) SO2R ' , -N (R ' ) SO2N (R- ) 2 , -N(R' JC(OJOR' , -N(R1JC (O)R' , -N(R1JC(S)R1 , -N(R')C(O)N(R')2, -N(R' JC(S)N(R1 )2, -N(COR1JCOR' , -N(OR1JR' , -C(=NH)N(R' >2, -C (0) N (OR ' ) R ' , -C(=NOR')R' , -OP(O) (OR1J2, -P(O) (R') 2, -P(O) (OR')2, Or -P(O) (H) (OR') ;
R1 is: hydrogen- ,
(C1-C12) -aliphatic-,
(CS-ClO -cycloalkiyl- or -cycloalkenyl- ,
[ (C3-C10) -cycloalkyl or -cycloalkenyl] - (C1-C12) - aliphatic- ,
(C6-C10) -aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-,
(C3-C10) -heterocyclyl-,
(C6-C10) -heterocyclyl- (C1-C12) aliphatic-,
(C5-C10) -heteroar-yl-, or
(C5-C10J -heteroar-yl- (C1-C12) -aliphatic-; wherein R' is optionally substituted with up to 3 J groups; wherein two R' groups bound to the same atom form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, 0, S, SO, or 158
SO2, wherein said ring is optionally fused to a (C6- ClO) aryl, (C5-C10)heteroaryl, (C3-C10) cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J.
3. The compound according to claim 1 or claim 2, wherein Ar is phenyl, pyridyl, quinolinyl, pyrimidinyl, or naphthyl, wherein each group is optionally substituted with I7 2, or 3 J groups.
4. The compound according to claim 1 or claim 2, wherein Ar is
Figure imgf000010_0001
Figure imgf000010_0002
or
5. The compound according to claim 1 or claim 2, wherein Ar is :
Figure imgf000010_0003
159
6. The compound according to claim 1 or claim 2, wherein Ar is a 6 or a 10-membered aromatic ring having 0, 1, or 2 nitrogen heteroatoms, wherein 1, 2, or 3 ring atoms are optionally and independently substituted with J.
7. The compound according to any one of claims 1-6, wherein each J group on Ar is independently OR', MO2, CN, CF3, OCP3, R', COR', C(O)OR1, C (O)N(R' )2, SO2R1, SO2-N(R') 2, 1,2-methylenedioxy, 1,2-ethylene dioxy, or NR1C(O)OR', NR'SO2R' .
8. The compound according to any one of claims 1-6, wherein each J group on Ar is independently OR', halogen, CN, CF3, R1 , or COR' .
9. The compound according to any one of claims 1-6, wherein each J group on Ar is independently halo, trifluoromethyl, methyl, or NO2.
10. The compound according to any one of claims 1- 9, wherein W is :
Figure imgf000011_0001
wherein the NR6R6 is -NH- (C1-C6 aliphatic) , -NH-(C3-C6 cycloalkyl) , -NH-CH(CH3) -aryl, or -NH-CH(CH3) -heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with up to 3 halogens.
11. The compound according to any one of claims 1- 10, wherein in the W, the NR6R6 is:
Figure imgf000012_0001
12. The compound according to any one of claims 1- 10, wherein in the W, the NR6R6 is:
Figure imgf000012_0002
13. The compound according to any one of claims 1- 10, wherein in the W, the NR6R5 is:
Figure imgf000012_0003
14. The compound according to any one of claims 1- 10, wherein in the W, the NR6R6 is:
Figure imgf000012_0004
161
15. Title compound according to any one of claims 1- 4, wherein R3' is hydrogen and R3 is:
Figure imgf000013_0001
16. The compound according to any one of claims 1- 4, wherein. R3' is hydrogen and R3 is:
Figure imgf000013_0002
17 . The compound according to any one of claims 1 - 6 , wherein. R2 is :
Figure imgf000013_0003
18 . The compound according to claim 17 , wherein R2 s :
Figure imgf000013_0004
19. The compound according to claim 18, wherein R2 is :
Figure imgf000014_0001
20. The compound according to any one of claims 1- 19, wherein R1 is:
Figure imgf000014_0002
21. The compound according to claim 20, wherein R1 i s :
Figure imgf000014_0003
22. The compound according to claim 21, wherein R1 is cyclohexyl .
23. The compoxmd according to any one of claims 1- 22, wherein T is (C6-C10) -aryl- or (C5-C10)heteroaryl-, wherein each T is optionally substituted with 1, 2, or 3 J substituents.
24. The compound according to any one of claims 1- 22, wherein T is:
Figure imgf000015_0001
wherein each T group is optionally fused to a 5-membered or a 6-membered aryl or heteπroaryl group.
25. The compound according to claim 24, wherein T is :
Figure imgf000015_0002
26. The compound according to claim 1 wherein, the compound is :
164
Figure imgf000016_0001
Figure imgf000017_0001
166
Figure imgf000018_0001
Figure imgf000019_0001
168
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
174
Figure imgf000026_0001
175
Figure imgf000027_0001
176
Figure imgf000028_0001
177
Figure imgf000029_0001
178
Figure imgf000030_0001
179
Figure imgf000031_0001
180
Figure imgf000032_0001
181
Figure imgf000033_0001
182
Figure imgf000034_0001
183
Figure imgf000035_0001
184
Figure imgf000036_0001
185
Figure imgf000037_0001
186
Figure imgf000038_0001
187
Figure imgf000039_0001
188
Figure imgf000040_0001
189
Figure imgf000041_0001
190
Figure imgf000042_0001
191
Figure imgf000043_0001
192
Figure imgf000044_0001
27. A composition comprising a compound according to any one of claims 1-26 or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit a serine protease; and a acceptable carrier, adjuvant or vehicle.
28. The composition according to claim 27, wherein said composition is formulated for administration to a patient.
29. The composition according to claim 28, wherein said composition comprises an additional agent selected 193 from an immunomodulatory agent; an antiviral agent; a second inhibitor of HCV protease; an inhibitor of another target in the HCV life cycle; a cytochrome P-450 inhibitor; or combinations thereof.
30. The composition according to claim 29, wherein said immunomodulatory agent is α-, β-, or γ-interferon or thymosin; the antiviral agent is ribavirin, amantadine, or telbivudine; or the inhibitor of another target in the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.
31. The composition according to claim 30, wherein said cytochrome P-450 inhibitor is ritonavir.
32. A method of inhibiting the activity of a serine protease comprising the step of contacting said serine protease with a compound according to any one of claims 1-26.
33. The method according to claim 32, wherein said protease is an HCV NS3 protease.
34. A method of treating an HCV infection in a patient comprising the step of administering to said patient a composition according to claim 27.
35. The method according to claim 34, comprising the additional step of administering to said patient an additional agent selected from an immunomodulatory agent; an antiviral agent; a second inhibitor of HCV protease; an inhibitor of another target in the HCV life cycle; or combinations thereof; wherein said additional agent is 194 administered to said patient as part of said composition according to claim 30 or as a separate dosage for-τn.
36. The method according to claim 35, wherein said immunomodulatory agent is α—, β-, or γ-interferon or thymosin; said antiviral agent is ribavarin or amantadine; or said inhibitor of another target i_n the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.
37. A method of eliminating or reducing HCV contamination of a biological sample or medical or laboratory equipment, comprising the step of contacting said biological sample or medical or laboratory equipment with a compound according to any one of claims 1—26.
38. The method according to claim 37, wherein said sample or equipment is selected from a body fluid, biological tissue, a surgical instrument, a surgrLcal garment, a laboratory instrument, a laboratory garment, a blood or other body fluid collection apparatus; s blood or other bodily fluid storage material.
39. The method according to claim 38, wherein said body fluid is blood.
40. A process for preparing a compound of formula I, as defined in any one of claims 1-26, comprising the step of: reacting a compound of formula II in the presence of a compound of formula III to provide a compound of formula IV:
Figure imgf000047_0001
II III IV wherein:
R10 is an amine protecting group, a P3- residue of an HCV protease inhibitor described herein, or a P4-P3- residue of an HCV protease inhibitor as described herein, and wherein the P3 and the P4-P3 residues are optionally protected the an amino-terminal capping group; R11 is a carboxy protecting group or a Pl residue of an HCV protease inhibitor described herein, wherein the Pl residue is optionally substituted at the terminal carboxy position with a carboxy protecting group or with W.
PCT/US2004/029093 2003-09-05 2004-09-07 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease WO2005035525A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2004279800A AU2004279800B9 (en) 2003-09-05 2004-09-07 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP04809688A EP1667998A2 (en) 2003-09-05 2004-09-07 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP2006525519A JP4767852B2 (en) 2003-09-05 2004-09-07 Inhibitors of serine proteases, especially HCV NS3-NS4A
CA2536436A CA2536436C (en) 2003-09-05 2004-09-07 2-amido-4-aryloxy-1-carbonyl pyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MXPA06002476A MXPA06002476A (en) 2003-09-05 2004-09-07 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease.
NZ545158A NZ545158A (en) 2003-09-05 2004-09-07 2-Amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CN2004800254182A CN1845920B (en) 2003-09-05 2004-09-07 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly HCV NS3-NS4A protease
BRPI0414176-8A BRPI0414176A (en) 2003-09-05 2004-09-07 serine protease inhibitors, in particular hcv ns3-ns4a protease
IL173627A IL173627A0 (en) 2003-09-05 2006-02-09 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
NO20061426A NO20061426L (en) 2003-09-05 2006-03-29 Inhibitors of serine proteases, especially HCV NS3-NS4A protease
HK07102734.0A HK1095594A1 (en) 2003-09-05 2007-03-13 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50067003P 2003-09-05 2003-09-05
US60/500,670 2003-09-05

Publications (3)

Publication Number Publication Date
WO2005035525A2 WO2005035525A2 (en) 2005-04-21
WO2005035525A3 WO2005035525A3 (en) 2005-10-20
WO2005035525B1 true WO2005035525B1 (en) 2006-04-06

Family

ID=34434831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/029093 WO2005035525A2 (en) 2003-09-05 2004-09-07 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Country Status (20)

Country Link
US (4) US7378422B2 (en)
EP (2) EP2573083A1 (en)
JP (2) JP4767852B2 (en)
KR (2) KR20120051751A (en)
CN (2) CN102408469A (en)
AR (1) AR045596A1 (en)
AU (1) AU2004279800B9 (en)
BR (1) BRPI0414176A (en)
CA (1) CA2536436C (en)
HK (1) HK1095594A1 (en)
IL (1) IL173627A0 (en)
MX (1) MXPA06002476A (en)
MY (1) MY148123A (en)
NO (1) NO20061426L (en)
NZ (2) NZ545158A (en)
PE (1) PE20050374A1 (en)
RU (2) RU2440368C2 (en)
TW (2) TW201127828A (en)
UY (1) UY28500A1 (en)
WO (1) WO2005035525A2 (en)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2409985A3 (en) 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
IL152022A0 (en) * 2000-04-03 2003-04-10 Vertex Pharma Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
SV2003000617A (en) * 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
JP2003007697A (en) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc Method for manufacturing semiconductor device, method and apparatus for processing substrate
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
KR20120013450A (en) 2003-07-18 2012-02-14 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1664091A1 (en) 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
KR20060130027A (en) * 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
ATE416789T1 (en) * 2003-10-27 2008-12-15 Vertex Pharma COMBINATIONS FOR HCV TREATMENT
AU2005212257A1 (en) * 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
KR20080016597A (en) 2005-05-13 2008-02-21 바이로켐 파마 인코포레이티드 Compounds and methods for the treatment or prevention of flavivirus infections
JP5160415B2 (en) * 2005-06-02 2013-03-13 メルク・シャープ・アンド・ドーム・コーポレーション Pharmaceutical formulation and therapeutic method using the same
TWI449711B (en) * 2005-06-30 2014-08-21 Virobay Inc Hcv inhibitors
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US20090148407A1 (en) * 2005-07-25 2009-06-11 Intermune, Inc. Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
CN101277950B (en) 2005-08-02 2013-03-27 弗特克斯药品有限公司 Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (en) * 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
ATE493409T1 (en) 2005-10-11 2011-01-15 Intermune Inc COMPOUNDS AND METHODS FOR INHIBITING HEPATITIS C VIRUS REPLICATION
JP5260062B2 (en) * 2006-01-20 2013-08-14 株式会社カネカ Process for producing β-amino-α-hydroxy acid amide derivative
WO2007089618A2 (en) * 2006-01-27 2007-08-09 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
CN102614490A (en) 2006-02-27 2012-08-01 弗特克斯药品有限公司 Co-crystals having VX-950 and pharmaceutical compositions comprising the same
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
US20070287664A1 (en) * 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
RU2448976C2 (en) 2006-04-11 2012-04-27 Новартис Аг Hcv/hiv inhibitors and their application
KR101069051B1 (en) 2006-05-23 2011-09-29 아이알엠 엘엘씨 Compounds and compositions as channel activating protease inhibitors
US7834190B2 (en) * 2006-05-26 2010-11-16 Kaneka Corporation Process for production of optically active-3-amino-2-hydroxypropionic cyclopropylamide derivatives and salts thereof
RU2008152171A (en) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) NEW HEPATITIS C VIRAL REPLICATION INHIBITORS
EP1881001A1 (en) * 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
CA2656816A1 (en) * 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
KR20090086081A (en) 2006-11-15 2009-08-10 바이로켐 파마 인코포레이티드 Thiophene analogues for the treatment or prevention of flavivirus infections
WO2008086053A1 (en) * 2007-01-03 2008-07-17 Virobay, Inc. Hcv inhibitors
BRPI0807483A2 (en) 2007-02-09 2014-05-13 Irm Llc COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATE PROTEASE INHIBITORS
CA2679426A1 (en) * 2007-02-27 2008-09-04 Luc Farmer Inhibitors of serine proteases
ATE542815T1 (en) * 2007-02-27 2012-02-15 Vertex Pharma COCRYSTALS AND PHARMACEUTICAL COMPOSITIONS THEREOF
US20080317712A1 (en) * 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
US7910587B2 (en) * 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US20080292587A1 (en) * 2007-04-26 2008-11-27 Ying Sun Oximyl dipeptide hepatitis c protease inhibitors
US20090155209A1 (en) * 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
EP2185524A1 (en) 2007-05-10 2010-05-19 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
JP5443360B2 (en) 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド Co-crystal and pharmaceutical composition containing the same
MX2010003916A (en) 2007-10-10 2010-05-05 Novartis Ag Spiropyrrolidines and their use against hcv and hiv infection.
JP2011051896A (en) * 2007-12-21 2011-03-17 Kaneka Corp Method for producing n-cyclopropyl-3-amino-2-hydroxyhexanoic acid amide hydrochloride
MX2010008109A (en) * 2008-01-24 2010-09-22 Enanta Pharm Inc Difluorinated tripeptides as hcv serine protease inhibitors.
AU2009210789B2 (en) * 2008-02-04 2014-01-30 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8321151B2 (en) 2008-12-30 2012-11-27 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8073633B2 (en) * 2008-12-30 2011-12-06 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8315815B2 (en) 2008-12-30 2012-11-20 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
CA2781614A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
US20130072523A1 (en) 2009-12-24 2013-03-21 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
MX2012010919A (en) 2010-03-24 2013-02-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections.
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AR081691A1 (en) 2010-06-28 2012-10-10 Vertex Pharma THIOPHEN DERIVATIVES, METHODS FOR PREPARATION AND USE IN THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
BR112013008100A2 (en) 2010-09-22 2016-08-09 Arena Pharm Inc "gpr19 receptor modulators and the treatment of disorders related thereto."
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
TW201317223A (en) 2011-07-26 2013-05-01 Vertex Pharma Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
AR091310A1 (en) * 2012-02-16 2015-01-28 Rqx Pharmaceuticals Inc ANTIBIOTICS OF LINEAR PEPTIDES
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CN116850181A (en) 2015-01-06 2023-10-10 艾尼纳制药公司 Treatment and S1P 1 Methods of receptor-related disorders
MX2017016530A (en) 2015-06-22 2018-03-12 Arena Pharm Inc Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluo romethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)a cetic acid(compound1) for use in sipi receptor-associated disorders.
CN108699106B (en) 2016-03-04 2021-11-30 豪夫迈·罗氏有限公司 Novel trifluoromethylpropionamide derivatives as HTRA1 inhibitors
JP2019507176A (en) 2016-03-04 2019-03-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel difluoroketamide derivatives as HTRA1 inhibitors
JP7164521B2 (en) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー carbocyclic prolinamide derivatives
CN114685453A (en) 2016-06-21 2022-07-01 奥瑞恩眼科有限责任公司 Heterocyclic prolinamide derivatives
JP2019522673A (en) 2016-07-18 2019-08-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel difluoroketoamide derivatives as HTRA1 inhibitors
EP3504197B1 (en) * 2016-08-23 2021-11-17 F. Hoffmann-La Roche AG New trifluoromethylpropanamide derivatives as htra1 inhibitors
JP2019526563A (en) 2016-08-23 2019-09-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel difluoroketamide derivatives as HTRA1 inhibitors
CN110520124A (en) 2017-02-16 2019-11-29 艾尼纳制药公司 For treating the Compounds and methods for of primary biliary cholangitis
US20220099637A1 (en) 2018-12-04 2022-03-31 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
WO2024099908A1 (en) 2022-11-09 2024-05-16 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3226768A1 (en) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF
DE3211676A1 (en) 1982-03-30 1983-10-06 Hoechst Ag NEW DERIVATIVES OF CYCLOALKA (C) PYRROL CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF AND NEW CYCLOALKA (C) PYRROL CARBONIC ACIDS AS THE INTERMEDIATE LEVELS AND METHODS
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
FR2575753B1 (en) 1985-01-07 1987-02-20 Adir NOVEL PEPTIDE DERIVATIVES WITH NITROGEN POLYCYCLIC STRUCTURE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5496927A (en) 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
DE3683541D1 (en) 1985-06-07 1992-03-05 Ici America Inc SELECTED DIFLUOR COMPOUNDS.
US5231084A (en) 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
NZ223148A (en) 1987-01-16 1989-10-27 Merrell Dow Pharma Peptide derivatives having peptidase inhibition activity
EP0356595A1 (en) 1988-09-01 1990-03-07 Merrell Dow Pharmaceuticals Inc. Novel peptidase inhibitors
US5736520A (en) 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
EP0371179A1 (en) 1988-10-28 1990-06-06 Merrell Dow Pharmaceuticals Inc. Novel analogs of peptidase substrates
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
JPH06504547A (en) 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション Peptide ketoamides, keto acids and ketoesters
CA2137832C (en) 1992-06-12 2000-09-26 Dennis J. Hoover Inhibitors of angiotensin i chymase(s) including human heart chymase
US5371072A (en) 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
DE69329544T2 (en) * 1992-12-22 2001-05-31 Eli Lilly And Co., Indianapolis HIV protease inhibiting compounds
DK0727419T3 (en) 1992-12-29 2002-06-10 Abbott Lab Intermediates for the preparation of compounds that inhibit retroviral protease
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5656600A (en) 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
RU95104898A (en) 1994-03-31 1996-12-27 Бристоль-Мейерз Сквибб Компани (US) Imedazole containing inhibitors of ferneside proteintansferase, and method of treatment diseases related therewith
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
EP1019410A1 (en) 1995-11-23 2000-07-19 MERCK SHARP & DOHME LTD. Spiro-piperidine derivatives and their use as tachykinin antagonists
JP2000502332A (en) 1995-12-07 2000-02-29 ザ スクリップス リサーチ インスティテュート HIV protease inhibitor
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
NZ332405A (en) 1996-04-23 2000-06-23 Vertex Pharma oxazolyl, thiazolyl or phenyl urea derivatives as inhibitors of inosine monophosphate dehydrogenase enzyme
WO1997043310A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
EP0929554B1 (en) 1996-09-25 2006-03-15 MERCK SHARP & DOHME LTD. Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists
CA2268255A1 (en) 1996-10-08 1998-04-16 Colorado State University Research Foundation Catalytic asymmetric epoxidation
EP2409985A3 (en) * 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE19648011A1 (en) 1996-11-20 1998-05-28 Bayer Ag Cyclic imines
DE19648793A1 (en) 1996-11-26 1998-05-28 Basf Ag New benzamides and their application
ES2201452T3 (en) 1997-03-14 2004-03-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF THE IMPDH ENZYME.
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
GB9708484D0 (en) 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
GB9711114D0 (en) 1997-05-29 1997-07-23 Merck Sharp & Dohme Therapeutic agents
ES2241157T3 (en) 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. INHIBITING PEPTIDES OF HEPATITIS C.
ES2234144T3 (en) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. ANALOGS OF INHIBITING PEPTIDES OF HEPATITIS C.
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6183121B1 (en) 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6211338B1 (en) * 1997-11-28 2001-04-03 Schering Corporation Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
IT1299134B1 (en) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio PROCEDURE FOR THE PRODUCTION OF PEPTIDES WITH PROTEAS INHIBITING THE NS3 PROTEASIS OF THE HCV VIRUS, PEPTIDES SO OBTAINABLE AND PEPTIDES
EP1066247B1 (en) 1998-03-31 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6251583B1 (en) 1998-04-27 2001-06-26 Schering Corporation Peptide substrates for HCV NS3 protease assays
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (en) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH .
DE19836514A1 (en) 1998-08-12 2000-02-17 Univ Stuttgart Modification of engineering polymers with N-basic groups and ion exchange groups in the side chain gives membranes of good thermal and mechanical stability useful for fuel cells, diffusion dialysis, electrodialysis, and reverse osmosis
US6117639A (en) 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
US6686335B1 (en) 1998-09-22 2004-02-03 Cephalon, Inc. Hydroxamate-containing cysteine and serine protease inhibitors
US6025516A (en) 1998-10-14 2000-02-15 Chiragene, Inc. Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
US6117870A (en) 1998-11-12 2000-09-12 Fujirebio Kabushiki Kaisha Cyclic amide derivatives
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
ES2306646T3 (en) 1999-02-09 2008-11-16 Pfizer Products Inc. COMPOSITIONS OF BASIC PHARMACOS WITH INCREASED BIODISPONIBILITY.
US20020042046A1 (en) 1999-02-25 2002-04-11 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
TR200103428T2 (en) 1999-03-19 2002-04-22 Vertex Pharmaceuticals Incorporated IMPDH enzyme inhibitors.
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
AU5920400A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
EP1206449A1 (en) 1999-07-26 2002-05-22 Bristol-Myers Squibb Company Lactam inhibitors of hepatitis c virus ns3 protease
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
EP1226237A2 (en) 1999-08-31 2002-07-31 Basf Aktiengesellschaft Method of identifying inhibitors of cdc25
US20020183249A1 (en) 1999-08-31 2002-12-05 Taylor Neil R. Method of identifying inhibitors of CDC25
GB9925955D0 (en) 1999-11-02 1999-12-29 Angeletti P Ist Richerche Bio Hcv n33 protease inhibitors
CA2390349A1 (en) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
AU2001234837A1 (en) 2000-02-08 2001-08-20 Schering Corporation Azapeptides useful in the treatment of hepatitis c
EP1261611A2 (en) 2000-02-29 2002-12-04 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
IL152022A0 (en) * 2000-04-03 2003-04-10 Vertex Pharma Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
KR20030036152A (en) 2000-04-05 2003-05-09 쉐링 코포레이션 Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties
NZ521456A (en) 2000-04-19 2004-07-30 Schering Corp Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
EP2289888A3 (en) 2000-06-30 2011-07-13 Seikagaku Corporation Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
WO2002007761A1 (en) 2000-07-20 2002-01-31 Merck & Co., Inc. Inhibiting hepatitis c virus processing and replication
AR034127A1 (en) 2000-07-21 2004-02-04 Schering Corp IMIDAZOLIDINONES AS INHIBITORS OF NS3-SERINA PROTEASA OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
DK1385870T3 (en) 2000-07-21 2010-07-05 Schering Corp Peptides as inhibitors of NS3 serine protease from hepatitis C virus
AR029851A1 (en) * 2000-07-21 2003-07-16 Dendreon Corp NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SV2003000617A (en) * 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
US6939692B2 (en) 2000-09-12 2005-09-06 Degussa Ag Nucleotide sequences coding for the pknB gene
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
JP2002198723A (en) * 2000-11-02 2002-07-12 Ace Technol Co Ltd Wideband directional antenna
US6602718B1 (en) 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
EP1337550B1 (en) 2000-11-20 2006-05-24 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
CN1301994C (en) 2000-12-12 2007-02-28 先灵公司 Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
AU2002230764A1 (en) 2000-12-13 2002-06-24 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
JP4848528B2 (en) 2000-12-28 2011-12-28 株式会社Ｉｈｉ Ion mass separation method and apparatus, and ion doping apparatus
EP1539188B1 (en) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
WO2002061149A2 (en) 2001-01-30 2002-08-08 Vertex Pharmaceuticals Incorporated A quantitative assay for nucleic acids
ES2328466T3 (en) 2001-03-27 2009-11-13 Vertex Pharmaceuticals Incorporated COMPOSITIONS AND USEFUL METHODS FOR HCV INFECTION.
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
AU2002354739A1 (en) 2001-07-03 2003-01-21 Altana Pharma Ag Process for the production of optically active 3-phenylisoserine
WO2003006490A1 (en) * 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
JP2003055389A (en) 2001-08-09 2003-02-26 Univ Tokyo Complex and method for producing epoxide therewith
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
EP1441720B8 (en) * 2001-10-24 2012-03-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
WO2003048135A1 (en) 2001-11-14 2003-06-12 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of losartan potassium and process for their preparation
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
AR038375A1 (en) 2002-02-01 2005-01-12 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE PROTEIN OF TRANSFER OF ESTERES DE COLESTERILO
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
PL373399A1 (en) 2002-04-11 2005-08-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
PL217947B1 (en) 2002-04-25 2014-09-30 Ono Pharmaceutical Co Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
CA2494340C (en) 2002-08-01 2012-01-24 Pharmasset Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
CA2413705A1 (en) 2002-12-06 2004-06-06 Raul Altman Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
BRPI0407587A (en) 2003-02-18 2006-02-14 Pfizer hepatitis c virus inhibitors, compositions and treatments that use them
ATE486889T1 (en) 2003-03-05 2010-11-15 Boehringer Ingelheim Int PEPTIDE ANALOGUES WITH INHIBITORY EFFECT ON HEPATITIS C
WO2004101605A1 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ATE547412T1 (en) * 2003-04-11 2012-03-15 Vertex Pharma INHIBITORS OF SERINE PROTEASES, IN PARTICULAR HCV NS3-NS4A PROTEASE
UY28323A1 (en) 2003-05-21 2004-12-31 Boehringer Ingelheim Int INHIBITING COMPOUNDS OF HEPATITIS C
KR20120013450A (en) * 2003-07-18 2012-02-14 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NZ545871A (en) 2003-09-12 2010-04-30 Vertex Pharma Animal model for protease activity and liver damage
EP1664091A1 (en) * 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US6933760B2 (en) 2003-09-19 2005-08-23 Intel Corporation Reference voltage generator for hysteresis circuit
PE20050431A1 (en) 2003-09-22 2005-07-19 Boehringer Ingelheim Int MACROCYCLIC PEPTIDES ACTIVE AGAINST HEPATITIS C VIRUS
KR20060130027A (en) * 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AR045870A1 (en) 2003-10-11 2005-11-16 Vertex Pharma COMBINATION THERAPY FOR HEPATITIS C VIRUS INFECTION
KR20060120166A (en) 2003-10-27 2006-11-24 버텍스 파마슈티칼스 인코포레이티드 Hcv ns3-ns4a protease resistance mutants
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
ATE416789T1 (en) 2003-10-27 2008-12-15 Vertex Pharma COMBINATIONS FOR HCV TREATMENT
WO2005042484A1 (en) 2003-10-28 2005-05-12 Vertex Pharmaceuticals, Incorporated Preparation of 4,5-dialkyl-3-acyl-pyrrole-2-carboxylic acid derivatives by fischer-fink type synthesis and subsequent acylation
US20050119318A1 (en) 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2007516706A (en) 2003-12-01 2007-06-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド Compositions containing fetal liver cells and methods useful in HCV infection
ES2358333T3 (en) 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh MACROCYCLIC PEPTIDES WITH ACTION AGAINST THE VIRUS OF HEPATITIS C.
AU2005212257A1 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
DE602005015834D1 (en) 2004-02-27 2009-09-17 Schering Corp 3,4- (CYCLOPENTYL) CONDENSED PROLIN LINES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS
WO2005090334A2 (en) 2004-03-12 2005-09-29 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
WO2005107745A1 (en) 2004-05-06 2005-11-17 Schering Corporation An inhibitor of hepatitis c
BRPI0511900A (en) * 2004-06-08 2008-01-22 Vertex Pharma pharmaceutical compositions
JP2008511633A (en) 2004-08-27 2008-04-17 シェーリング コーポレイション Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
CN101072575A (en) * 2004-10-01 2007-11-14 威特克斯医药股份有限公司 Hcv ns3-ns4a protease inhibition
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
CN101277950B (en) * 2005-08-02 2013-03-27 弗特克斯药品有限公司 Inhibitors of serine proteases
ES2449268T3 (en) * 2005-08-19 2014-03-19 Vertex Pharmaceuticals Inc. Processes
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (en) * 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CN102614490A (en) 2006-02-27 2012-08-01 弗特克斯药品有限公司 Co-crystals having VX-950 and pharmaceutical compositions comprising the same
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
KR101398259B1 (en) 2006-03-16 2014-05-26 버텍스 파마슈티칼스 인코포레이티드 Processes and intermediates for preparing steric compounds
CN101494979A (en) 2006-03-20 2009-07-29 沃泰克斯药物股份有限公司 Pharmaceutical compositions
KR20140107691A (en) 2006-03-20 2014-09-04 버텍스 파마슈티칼스 인코포레이티드 Pharmaceutical compositions
US7651520B2 (en) * 2006-05-30 2010-01-26 Ostial Solutions, Llc Means and method for the accurate placement of a stent at the ostium of an artery
ATE481089T1 (en) 2006-05-31 2010-10-15 Vertex Pharma ORAL FORMULATIONS WITH CONTROLLED RELEASE OF AN INTERLEUKIN-1 BETA-CONVERTING ENZYME INHIBITOR
US7708294B2 (en) 2006-11-02 2010-05-04 Gm Global Technology Operations, Inc. Detachable dual-use platform apparatus and method
CA2679426A1 (en) 2007-02-27 2008-09-04 Luc Farmer Inhibitors of serine proteases
US7910587B2 (en) * 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US7959488B2 (en) * 2007-10-15 2011-06-14 Tania Alessandra Talamo Brassiere pad system

Similar Documents

Publication Publication Date Title
WO2005035525B1 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2536436A1 (en) 2-amido-4-aryloxy-1-carbonyl pyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2481369A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
JP2007504251A5 (en)
JP2007532474A5 (en)
RU2441020C2 (en) Serine protease inhibitors
DE60217114T2 (en) BROKEN BICYCLIC SERINE PROTEASE INHIBITORS
JP4745230B2 (en) Inhibitors of serine proteases, in particular HCV NS3-NS4A protease
CN114057702B (en) Novel inhibitor of coronavirus main protease and preparation method and application thereof
JP2005535574A5 (en)
CA3189027A1 (en) Antiviral heteroaryl ketone derivatives
RU2006115558A (en) SERINE PROTEASES INHIBITORS, ESPECIALLY HCV NS3-NS4A PROTEASES
JP2006526011A5 (en)
CA2521678A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
PL192280B1 (en) Inhibitors of serinic proteases in particular that of hepatitis c virus ns3
CN115960088A (en) Novel coronavirus main protease inhibitor, preparation method and application thereof
JP2009506078A5 (en)
JP2010523591A (en) Antiviral treatment
Rönn et al. Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors
US20110064694A1 (en) Anti-hepatitis c activity of meso-tetrakis-porphyrin analogues
WO2013178782A1 (en) Allosteric inhibitors of ns3 protease from hepatitis c virus
CN108349945A (en) HCV inhibitor, preparation method and application
AU2012202576A1 (en) Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease